Product Images Lisdexamfetamine Dimesylate

Description: This text appears to be labeling information for a medication with the NDC number 0781-2299-01 containing Lisdexamfetamine dimesylate 10 mg per capsule. It instructs to store the medication at 20° to 25°C, in a specific container, and out of reach of children. The text also mentions that it is a pharmacy bulk package distributed by Sandoz Inc. Pharmacists are advised to dispense the medication guide included separately with each patient. The product consists of 100 capsules.*

This text contains information about a medication with the NDC code 0781-2476-01, which is a capsule containing Lisdexamfetamine dimesylate 20 mg. The medication should be stored at 20° to 25°C (68° to 77°F) in a tight, light-resistant container. The text emphasizes the importance of keeping the medication out of the reach of children. It also mentions that the package should be dispensed with a Medication Guide provided separately to each patient. Additionally, it notes the presence of color additives including FD&C Yellow #5 (tartrazine). The medication is distributed by Sandoz Inc. in Princeton, NJ. This is a pharmacy bulk package containing 100 capsules.*

This is a prescription medication with the NDC code 0781-2477-01 manufactured by SANDOZ. It contains Lisdexamfetamine dimesylate in 30 mg capsules, with each capsule being equivalent to 17.3 mg of lisdexamfetamine. The usual dosage instructions are provided in the package insert. The medication should be stored at 20°C to 25°C (68°F to 77°F) and dispensed in a light-resistant container with a child-resistant closure. It is important to keep this medication out of the reach of children. Instructions for dispensing the Medication Guide separately to each patient are included.*

This is a description for Lisdexamfetamine Dimesylate Capsules at 40 mg dosage, with NDC number 0781-2478-01 by Sandoz. Each capsule contains 40 mg of Lisdexamfetamine dimesylate. It is a pharmacy bulk package with 100 capsules. It also lists the color additives and instructions on storage and dosage. The medication guide should be dispensed separately to each patient.*

Each capsule of the medication contains 50 mg of Lisdexamfetamine dimesylate, equivalent to 28.9 mg of lisdexamfetamine. The medication is required to be stored at controlled room temperature between 68°F to 77°F. It is distributed by Sandoz Inc. and comes in a pharmacy bulk package. Pharmacists are instructed to dispense the medication with a Medication Guide provided separately to each patient. This particular package contains 100 capsules.*

The text provides information about a medication with NDC number 0781-2480-01 containing Lisdexamfetamine dimesylate 60 mg per capsule. It instructs to store the medication at 20° to 25°C and dispense it in a tight, light-resistant container with a child-resistant closure. The product warns to keep it out of the reach of children and includes details about the distributor, Sandoz Inc. Pharmacies are advised to dispense the medication along with a separate Medication Guide for each patient. This product comes in a pharmacy bulk package with 100 capsules.*

This text provides detailed information about the prescription drug Lisdexamfetamine Dimesylate capsules. Each capsule contains 70 mg of Lisdexamfetamine Dimesylate, equivalent to 40.5 mg of lisdexamfetamine. The usual dosage instructions can be found in the package insert. It is recommended to store the capsules at 20° to 25°C (68° to 77°F) and keep them in a tight, light-resistant container with a child-resistant closure. A Medication Guide is provided separately for each patient. The drug is distributed by Sandoz Inc. and the package is a pharmacy bulk package. The text also includes the NDC code, prescription-only label, and other regulatory information.*

This text provides information on how different variables can affect the pharmacokinetics of a drug in special populations, such as different age groups and renal impairment levels. It includes data on changes in Cmax (maximum plasma concentration) and AUC (area under the curve) values for these populations compared to a reference group.*

This text appears to be a table or data comparison related to changes in some variables such as Guanfacine, Venlafaxine, PK, AUC, and Fold Change with 90% confidence interval. It presents values that seem to be related to changes relative to a reference parameter. The specific details or context of the comparison are not provided in the extracted text. It may be part of a scientific study, medical research, or a similar analytical report.*

This text lists various drugs and their interactions with different cytochrome P450 (CYP) enzymes. It mentions guanfacine and venlafaxine as interacting drugs, along with different substrates for CYP1A2, CYP2D6, CYP2C19, and CYP3A enzymes. The text also refers to fold change and confidence intervals regarding these interactions.*

This text provides LS Mean (SE) SKAMP Deportment Scores for Placebo and Lisdexamfetamine Dimesylate at different time points post-dose (5, 15, 28, 75 hours) such as 10, 12, and 13 hours. The information appears to be related to a study or evaluation of the effects of these substances on deportment scores.*

This text indicates LS Mean (SE) PERMP Total Scores for Placebo and Lisdexamfetamine Dimesylate at different time points post-dose in hours. The scores range from 200 to 330. The data suggests a comparison of the efficacy of the two treatments over time in improving PERMP Total Scores.*

This text provides a graph showing the proportion of subjects with relapse/treatment failure over time in a study comparing placebo with Lisdexamfetamine Dimesylate. The x-axis represents time in days after randomization, and the y-axis shows the percentage of subjects experiencing relapse or treatment failure. The data suggests a difference in outcomes between the two treatments.*